Independent Advisor Alliance’s NovoCure NVCR Stock Holding History

Independent Advisor Alliance’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,164	Closed	-$311K	–	696
2023 Q1	$311K	Buy	+5,164	New	+$413K	0.02%	509
2022 Q4	–	Sell	-4,522	Closed	-$344K	–	562
2022 Q3	$344K	Buy	4,522 +224	+5%	+$17.5K	0.02%	457
2022 Q2	$299K	Sell	4,298 -20	-0.5%	-$1.51K	0.02%	483
2022 Q1	$358K	Sell	4,318 -155	-3%	-$11.4K	0.02%	476
2021 Q4	$336K	Sell	4,473 -122	-3%	-$12.2K	0.02%	491
2021 Q3	$534K	Sell	4,595 -535	-10%	-$80.9K	0.03%	362
2021 Q2	$1.14M	Buy	5,130 +52	+1%	+$10.1K	0.06%	253
2021 Q1	$671K	Sell	5,078 -48	-0.9%	-$7.59K	0.04%	316
2020 Q4	$887K	Buy	5,126 +246	+5%	+$33.7K	0.06%	234
2020 Q3	$543K	Sell	4,880 -978	-17%	-$78.2K	0.04%	274
2020 Q2	$347K	Buy	+5,858	New	+$385K	0.04%	341

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Independent Advisor Alliance's NVCR Position: Q2 2023 in Review

Independent Advisor Alliance sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 5,164 shares — an estimated $311K sold.

Independent Advisor Alliance first reported a position in NVCR in Q2 2020 and held it in 11 quarters. The position peaked at $1.14M in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Independent Advisor Alliance reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
Independent Advisor Alliance sold 5,164 NovoCure shares in Q2 2023, an estimated $311K.
Independent Advisor Alliance first reported a position in NovoCure in Q2 2020 and held it in 11 quarters.
Independent Advisor Alliance's NovoCure position peaked at $1.14M in Q2 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Independent Advisor Alliance's 13F filing for Q2 2023, filed 28 Jul 2023.